Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Everett E. Vokes

Concepts (651)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Head and Neck Neoplasms
105
2021
978
18.190
Why?
Lung Neoplasms
142
2021
2046
15.570
Why?
Antineoplastic Combined Chemotherapy Protocols
122
2021
2226
15.500
Why?
Carcinoma, Non-Small-Cell Lung
99
2021
939
15.460
Why?
Carcinoma, Squamous Cell
75
2021
1031
10.190
Why?
Antineoplastic Agents
74
2018
2335
5.960
Why?
Chemoradiotherapy
29
2021
254
5.630
Why?
Neoplasm Recurrence, Local
48
2020
1172
5.080
Why?
Small Cell Lung Carcinoma
20
2021
81
4.170
Why?
Carboplatin
39
2021
256
3.700
Why?
Combined Modality Therapy
62
2021
1638
3.600
Why?
Quinazolines
22
2015
221
3.470
Why?
Protein Kinase Inhibitors
21
2020
561
3.470
Why?
Aged
184
2021
18174
3.210
Why?
Paclitaxel
39
2021
449
3.100
Why?
Disease-Free Survival
57
2020
1196
2.910
Why?
Papillomavirus Infections
9
2020
153
2.900
Why?
Neoplasm Staging
71
2021
1901
2.900
Why?
Humans
315
2021
80573
2.750
Why?
Middle Aged
184
2021
25198
2.720
Why?
Aged, 80 and over
97
2021
6485
2.480
Why?
Male
201
2021
41070
2.410
Why?
Survival Rate
53
2020
1933
2.400
Why?
Female
203
2021
43727
2.320
Why?
Clinical Trials as Topic
24
2021
1185
2.300
Why?
Adult
149
2021
25416
2.230
Why?
Treatment Outcome
86
2021
7698
2.070
Why?
Adenocarcinoma
24
2016
1213
2.070
Why?
Carcinoma, Small Cell
11
2017
140
2.000
Why?
Cisplatin
30
2021
567
1.980
Why?
Taxoids
17
2017
131
1.970
Why?
Survival Analysis
45
2020
1586
1.970
Why?
Indoles
15
2017
327
1.920
Why?
Induction Chemotherapy
11
2016
119
1.890
Why?
Camptothecin
14
2013
194
1.870
Why?
Radiotherapy Dosage
30
2021
465
1.780
Why?
Oropharyngeal Neoplasms
5
2020
80
1.760
Why?
Radiotherapy
15
2011
341
1.700
Why?
Pyrroles
7
2017
217
1.670
Why?
Fluorouracil
25
2014
566
1.650
Why?
Radiation-Sensitizing Agents
6
2013
106
1.620
Why?
Mesothelioma
13
2017
286
1.550
Why?
Hydroxyurea
20
2014
229
1.500
Why?
Antibodies, Monoclonal
18
2021
1489
1.470
Why?
Laryngeal Neoplasms
5
2013
82
1.470
Why?
Mouth Neoplasms
9
2018
169
1.440
Why?
Chemotherapy, Adjuvant
20
2015
482
1.430
Why?
Deoxycytidine
14
2012
242
1.420
Why?
Angiogenesis Inhibitors
9
2016
287
1.370
Why?
Papillomaviridae
7
2020
114
1.370
Why?
Benzimidazoles
4
2021
136
1.360
Why?
Etoposide
15
2021
197
1.350
Why?
Sirolimus
3
2020
170
1.300
Why?
Proto-Oncogene Proteins c-met
15
2017
201
1.300
Why?
Drug Resistance, Neoplasm
12
2020
556
1.270
Why?
Medical Oncology
7
2021
321
1.240
Why?
Prognosis
44
2020
3621
1.160
Why?
Salvage Therapy
9
2014
223
1.120
Why?
Guanine
8
2014
205
1.070
Why?
Maximum Tolerated Dose
13
2018
265
1.050
Why?
Quality of Life
16
2017
1283
1.050
Why?
Esophageal Neoplasms
5
2012
349
1.030
Why?
Antibodies, Monoclonal, Humanized
18
2018
909
1.000
Why?
Liver Neoplasms
8
2018
615
1.000
Why?
Clinical Trials, Phase II as Topic
8
2017
170
1.000
Why?
Deglutition
9
2020
68
1.000
Why?
Neoplasms, Second Primary
8
2011
235
1.000
Why?
Clinical Trials, Phase III as Topic
10
2021
160
1.000
Why?
Vascular Endothelial Growth Factor A
10
2013
375
0.990
Why?
Randomized Controlled Trials as Topic
12
2021
847
0.970
Why?
Radiotherapy, Conformal
5
2011
87
0.940
Why?
Pancreatic Neoplasms
4
2010
693
0.930
Why?
Kaplan-Meier Estimate
17
2017
904
0.910
Why?
Disease Progression
22
2021
1441
0.900
Why?
Pleural Neoplasms
5
2020
181
0.890
Why?
Neoplasm Metastasis
19
2020
1037
0.890
Why?
Molecular Targeted Therapy
3
2020
271
0.880
Why?
Cyclooxygenase 2
4
2017
97
0.870
Why?
Carcinoma, Large Cell
7
2014
40
0.850
Why?
Thoracic Neoplasms
4
2018
59
0.800
Why?
Immunotherapy
5
2021
537
0.800
Why?
Enzyme Inhibitors
7
2014
672
0.800
Why?
Costs and Cost Analysis
1
2019
151
0.780
Why?
Glutamates
6
2014
92
0.750
Why?
Terminal Care
1
2019
137
0.730
Why?
Vinblastine
3
2002
108
0.730
Why?
Organoplatinum Compounds
4
2006
99
0.710
Why?
Drug Administration Schedule
17
2020
970
0.710
Why?
Radiotherapy, Adjuvant
12
2015
305
0.710
Why?
Carcinoma
7
2016
431
0.680
Why?
Peritoneal Neoplasms
4
2012
170
0.680
Why?
Stomach Neoplasms
3
2011
271
0.670
Why?
Human papillomavirus 16
2
2015
36
0.670
Why?
Colorectal Neoplasms
5
2011
828
0.670
Why?
Quality of Health Care
2
2019
354
0.670
Why?
Intracellular Signaling Peptides and Proteins
3
2014
367
0.660
Why?
Thionucleotides
2
2008
59
0.650
Why?
Follow-Up Studies
23
2020
3813
0.640
Why?
Time Factors
20
2021
5449
0.640
Why?
Organ Sparing Treatments
2
2013
34
0.640
Why?
Adenocarcinoma, Bronchiolo-Alveolar
3
2011
20
0.630
Why?
Neoplasms, Squamous Cell
2
2015
19
0.630
Why?
Receptor Protein-Tyrosine Kinases
5
2015
158
0.620
Why?
Speech
2
2013
69
0.610
Why?
Protein-Serine-Threonine Kinases
4
2014
543
0.600
Why?
Exanthema
3
2014
29
0.600
Why?
Neoplasms
14
2021
2569
0.600
Why?
Neoadjuvant Therapy
6
2012
271
0.590
Why?
Remission Induction
10
2014
701
0.590
Why?
Patient Selection
8
2021
688
0.580
Why?
Pyridines
5
2019
304
0.550
Why?
Neck Dissection
6
2010
73
0.540
Why?
Blood Proteins
1
2014
154
0.540
Why?
Neutropenia
6
2017
221
0.510
Why?
DNA Repair
2
2014
342
0.500
Why?
Neoplasm Invasiveness
6
2016
529
0.500
Why?
Radiotherapy, Intensity-Modulated
5
2016
161
0.500
Why?
Publishing
1
2013
87
0.490
Why?
Mutation
16
2017
3784
0.490
Why?
Protein-Tyrosine Kinases
6
2017
302
0.490
Why?
Proteomics
1
2014
187
0.490
Why?
Healthcare Disparities
1
2016
323
0.480
Why?
Antimetabolites, Antineoplastic
4
2013
248
0.480
Why?
Sulfonamides
9
2014
308
0.470
Why?
DNA-Binding Proteins
3
2015
1186
0.470
Why?
Proto-Oncogene Proteins c-cbl
3
2017
36
0.460
Why?
Lung
3
2013
1033
0.450
Why?
Cell Line, Tumor
19
2015
2401
0.450
Why?
Receptors, Growth Factor
5
2011
56
0.450
Why?
Retrospective Studies
24
2020
7293
0.450
Why?
Nasopharyngeal Neoplasms
3
2016
43
0.440
Why?
Gene Expression Regulation, Neoplastic
11
2017
1199
0.440
Why?
Area Under Curve
6
2018
340
0.440
Why?
Proportional Hazards Models
9
2019
869
0.440
Why?
Platinum
6
2019
52
0.440
Why?
Signal Transduction
11
2019
3274
0.430
Why?
Antineoplastic Agents, Phytogenic
5
2012
298
0.430
Why?
Maintenance Chemotherapy
3
2020
74
0.420
Why?
Methotrexate
2
2017
256
0.420
Why?
Receptor, EphB4
3
2015
27
0.410
Why?
Age Factors
7
2018
1902
0.400
Why?
Carmustine
2
2006
72
0.400
Why?
Piperazines
8
2019
264
0.400
Why?
O(6)-Methylguanine-DNA Methyltransferase
2
2006
118
0.390
Why?
Administration, Oral
9
2020
710
0.390
Why?
Cohort Studies
10
2021
2627
0.390
Why?
Dose-Response Relationship, Drug
14
2018
2083
0.390
Why?
Proto-Oncogene Proteins
5
2017
660
0.390
Why?
Arsenicals
1
2008
41
0.390
Why?
Oxides
1
2008
48
0.390
Why?
Prostatic Neoplasms
5
2011
1405
0.380
Why?
Fatigue
3
2018
164
0.370
Why?
Salivary Gland Neoplasms
4
2011
59
0.370
Why?
Double-Blind Method
5
2017
1857
0.370
Why?
Infusions, Intravenous
8
2018
448
0.370
Why?
Smoking
6
2014
563
0.360
Why?
Immunohistochemistry
10
2020
1806
0.360
Why?
Indazoles
4
2013
42
0.360
Why?
International Cooperation
3
2018
136
0.360
Why?
Deglutition Disorders
4
2011
80
0.350
Why?
Consolidation Chemotherapy
2
2018
21
0.350
Why?
Suramin
2
2004
27
0.350
Why?
Alkyl and Aryl Transferases
2
2003
15
0.340
Why?
Lymph Nodes
5
2019
525
0.340
Why?
Phosphorylcholine
1
2006
25
0.330
Why?
Pyrimidines
4
2012
380
0.330
Why?
Niacinamide
5
2013
117
0.330
Why?
DNA
1
2012
1292
0.330
Why?
Thiazoles
3
2012
130
0.320
Why?
Anemia
4
2017
125
0.320
Why?
Risk Factors
12
2018
5284
0.320
Why?
Benzenesulfonates
3
2010
64
0.320
Why?
Multivariate Analysis
8
2019
1025
0.320
Why?
Gene Rearrangement
2
2017
164
0.320
Why?
High-Throughput Nucleotide Sequencing
2
2020
405
0.320
Why?
Tubulin Modulators
2
2021
27
0.320
Why?
Platinum Compounds
2
2017
31
0.310
Why?
Practice Guidelines as Topic
3
2016
1065
0.310
Why?
Gallbladder Neoplasms
1
2005
31
0.310
Why?
Mouth
2
2018
52
0.310
Why?
Research Design
4
2015
557
0.310
Why?
Placebos
5
2015
226
0.310
Why?
Dacarbazine
1
2006
111
0.310
Why?
Proto-Oncogene Proteins c-bcl-2
3
2010
193
0.300
Why?
Bile Duct Neoplasms
1
2005
65
0.300
Why?
Neovascularization, Pathologic
2
2008
352
0.300
Why?
Antineoplastic Agents, Alkylating
1
2005
142
0.300
Why?
Confidence Intervals
5
2018
232
0.290
Why?
Boronic Acids
3
2011
55
0.290
Why?
Oligopeptides
1
2005
184
0.290
Why?
Imidazoles
4
2013
167
0.290
Why?
Radiation Dosage
3
2020
221
0.280
Why?
Pneumonectomy
3
2018
182
0.280
Why?
Pyrazines
3
2011
83
0.280
Why?
Mouthwashes
1
2003
5
0.280
Why?
Cyclosporine
1
2005
248
0.280
Why?
Xenograft Model Antitumor Assays
7
2017
455
0.280
Why?
Radiography
4
2014
864
0.280
Why?
Sarcoma
1
2006
228
0.280
Why?
Positron-Emission Tomography
2
2018
277
0.280
Why?
Viral Vaccines
1
2003
39
0.270
Why?
Cancer Care Facilities
1
2003
25
0.270
Why?
Immunoblotting
5
2017
279
0.260
Why?
Travel
1
2003
66
0.260
Why?
Tongue Neoplasms
3
2018
50
0.260
Why?
Quinolones
1
2003
54
0.260
Why?
United States
11
2021
6129
0.260
Why?
Gene Expression
5
2017
1322
0.250
Why?
Phosphorylation
7
2017
1148
0.250
Why?
Drug Eruptions
2
2017
38
0.250
Why?
TOR Serine-Threonine Kinases
3
2020
172
0.250
Why?
Cranial Irradiation
3
2018
36
0.240
Why?
Attitude to Health
1
2004
224
0.240
Why?
Brain Neoplasms
3
2012
790
0.240
Why?
Precancerous Conditions
1
2003
205
0.240
Why?
Chicago
4
2014
1418
0.240
Why?
Thrombocytopenia
2
2017
162
0.240
Why?
Receptors, Vascular Endothelial Growth Factor
3
2010
61
0.230
Why?
Melanoma
2
2005
495
0.230
Why?
Erythroid Precursor Cells
1
2021
31
0.230
Why?
Young Adult
9
2021
5788
0.230
Why?
Research Report
1
2021
37
0.230
Why?
Genomics
3
2016
611
0.230
Why?
Focal Adhesions
2
2013
69
0.230
Why?
Polymorphism, Genetic
4
2011
821
0.220
Why?
Paxillin
2
2013
61
0.220
Why?
Pyrrolidinones
1
2020
16
0.220
Why?
Prospective Studies
11
2014
3909
0.220
Why?
RNA, Small Interfering
8
2017
570
0.220
Why?
Sex Factors
4
2019
1080
0.210
Why?
Alphapapillomavirus
1
2020
18
0.210
Why?
Topoisomerase I Inhibitors
5
2013
36
0.210
Why?
Aminopyridines
1
2019
26
0.200
Why?
Mucositis
2
2017
22
0.200
Why?
Morpholines
1
2019
79
0.200
Why?
Quinolines
1
2020
95
0.200
Why?
Survival
3
2003
23
0.200
Why?
Immunosuppressive Agents
1
2005
1019
0.200
Why?
Predictive Value of Tests
4
2020
1688
0.200
Why?
Pharynx
1
2018
38
0.190
Why?
Epothilones
2
2009
13
0.190
Why?
Phenylurea Compounds
4
2013
108
0.190
Why?
Granulocyte Colony-Stimulating Factor
4
2011
164
0.190
Why?
Erythropoietin
3
2013
91
0.190
Why?
Hepatocyte Growth Factor
3
2014
83
0.190
Why?
Vascular Endothelial Growth Factor Receptor-2
3
2009
80
0.190
Why?
Radiation Injuries
2
2018
160
0.190
Why?
Health Resources
1
2019
77
0.190
Why?
Depsipeptides
2
2010
30
0.190
Why?
Gene Dosage
7
2013
216
0.190
Why?
Orthodontic Appliances
1
2018
8
0.190
Why?
Dental Alloys
1
2018
7
0.190
Why?
Radiation Pneumonitis
1
2018
16
0.190
Why?
Radiotherapy Planning, Computer-Assisted
3
2018
173
0.190
Why?
Hemoptysis
1
2018
23
0.190
Why?
DNA Topoisomerases, Type I
3
2013
27
0.180
Why?
Skin Neoplasms
2
2005
536
0.180
Why?
Vision Disorders
1
2018
68
0.180
Why?
Carcinoma, Renal Cell
3
2007
375
0.180
Why?
Transforming Growth Factor alpha
2
2009
52
0.180
Why?
Retreatment
3
2012
103
0.180
Why?
Immunoconjugates
1
2018
104
0.180
Why?
Gene Expression Profiling
4
2021
1357
0.180
Why?
Genotype
5
2015
1844
0.180
Why?
Mice, Nude
4
2012
778
0.170
Why?
Odds Ratio
4
2008
684
0.170
Why?
Intention to Treat Analysis
1
2017
68
0.170
Why?
Tomography, X-Ray Computed
4
2013
2535
0.170
Why?
Geriatric Assessment
1
2018
156
0.170
Why?
Pyrazoles
3
2011
157
0.170
Why?
Life Style
1
2018
182
0.170
Why?
In Situ Hybridization, Fluorescence
4
2012
356
0.170
Why?
Patient Acceptance of Health Care
1
2019
216
0.170
Why?
Paired Box Transcription Factors
2
2014
51
0.170
Why?
Carcinoma, Adenoid Cystic
2
2007
23
0.160
Why?
Statistics, Nonparametric
3
2009
323
0.160
Why?
Kidney Neoplasms
3
2007
558
0.160
Why?
Probability
3
2008
355
0.160
Why?
Lymphatic Metastasis
4
2014
506
0.160
Why?
SEER Program
1
2016
195
0.160
Why?
Mice
10
2021
10942
0.160
Why?
Recombinant Proteins
5
2010
1055
0.160
Why?
Animals
13
2021
26590
0.160
Why?
Cell Movement
6
2017
736
0.160
Why?
Fractals
1
2015
45
0.150
Why?
Endpoint Determination
1
2015
60
0.150
Why?
Antibody-Dependent Cell Cytotoxicity
1
2015
24
0.150
Why?
Bryostatins
2
2006
15
0.150
Why?
Platelet-Derived Growth Factor
2
2011
68
0.150
Why?
Cell Proliferation
8
2015
1596
0.150
Why?
Health Status
2
2009
350
0.150
Why?
Injections, Intravenous
2
2006
270
0.150
Why?
Radiation, Ionizing
2
2012
124
0.150
Why?
Receptors, Antigen, T-Cell
1
2017
388
0.150
Why?
Incidence
5
2018
1588
0.150
Why?
Isotretinoin
2
2006
21
0.140
Why?
Gene Knockout Techniques
1
2014
74
0.140
Why?
Mass Screening
2
2013
611
0.140
Why?
Treatment Failure
5
2010
306
0.140
Why?
Preoperative Care
3
2009
416
0.140
Why?
Tumor Virus Infections
1
2014
82
0.140
Why?
Tumor Microenvironment
1
2017
288
0.140
Why?
Socioeconomic Factors
1
2016
566
0.140
Why?
Cyclooxygenase 2 Inhibitors
2
2017
34
0.140
Why?
Gene Amplification
2
2018
134
0.140
Why?
Cell Survival
5
2017
1011
0.140
Why?
Population Groups
1
2013
41
0.140
Why?
Farnesyltranstransferase
2
2003
6
0.140
Why?
Leukocytes, Mononuclear
2
2005
181
0.140
Why?
Forecasting
2
2021
318
0.140
Why?
Hypopharyngeal Neoplasms
1
2013
14
0.140
Why?
Risk Assessment
7
2016
2243
0.130
Why?
Erythropoiesis
1
2013
48
0.130
Why?
Glucuronosyltransferase
2
2006
187
0.130
Why?
Alcohol Drinking
3
2018
267
0.130
Why?
Interferon-alpha
3
2010
239
0.130
Why?
Clinical Protocols
1
2013
153
0.130
Why?
Dehydration
1
2013
23
0.130
Why?
Pharmacogenetics
2
2008
387
0.130
Why?
Esophagitis
1
2013
42
0.130
Why?
Gene Deletion
1
2014
343
0.130
Why?
HeLa Cells
1
2014
504
0.130
Why?
Osteoradionecrosis
2
2010
15
0.130
Why?
Killer Cells, Natural
1
2015
301
0.130
Why?
Keratin-19
1
2012
11
0.130
Why?
Universities
2
2010
132
0.130
Why?
Ketones
1
2012
12
0.130
Why?
Furans
1
2012
15
0.130
Why?
Dexamethasone
2
2004
306
0.120
Why?
Arachidonate 5-Lipoxygenase
1
2011
23
0.120
Why?
Ribosomal Protein S6 Kinases, 70-kDa
1
2012
48
0.120
Why?
DNA Mutational Analysis
5
2017
542
0.120
Why?
Prostate-Specific Antigen
2
2004
305
0.120
Why?
Ovarian Neoplasms
2
2008
661
0.120
Why?
Phthalazines
1
2011
28
0.120
Why?
Genetic Testing
1
2016
490
0.120
Why?
Evidence-Based Medicine
2
2007
438
0.120
Why?
Cancer Vaccines
1
2013
153
0.120
Why?
Image Processing, Computer-Assisted
2
2015
1162
0.120
Why?
RNA, Viral
1
2013
343
0.120
Why?
Organ Preservation
1
2011
62
0.120
Why?
Radiotherapy, Image-Guided
1
2012
58
0.120
Why?
Genes, ras
1
2011
99
0.110
Why?
Neoplastic Cells, Circulating
1
2011
65
0.110
Why?
Periodicals as Topic
1
2013
166
0.110
Why?
Rad51 Recombinase
2
2014
81
0.110
Why?
Receptor, EphA2
1
2010
4
0.110
Why?
Mucins
1
2010
44
0.110
Why?
Community Networks
2
2018
35
0.110
Why?
Oncogene Proteins, Fusion
1
2011
116
0.110
Why?
Analysis of Variance
3
2011
954
0.110
Why?
Developing Countries
1
2010
73
0.110
Why?
Carcinosarcoma
1
2010
19
0.110
Why?
Antibiotics, Antineoplastic
1
2010
122
0.110
Why?
Health Facilities
1
2009
26
0.100
Why?
Antigens, Neoplasm
1
2012
323
0.100
Why?
Tissue Array Analysis
3
2017
128
0.100
Why?
Postoperative Period
1
2010
309
0.100
Why?
ras Proteins
1
2010
132
0.100
Why?
Diarrhea
3
2008
204
0.100
Why?
Biliary Tract Neoplasms
1
2009
33
0.100
Why?
Hematopoietic Stem Cells
1
2011
281
0.100
Why?
Mesna
1
2008
10
0.100
Why?
Postoperative Complications
2
2018
2245
0.100
Why?
Radiotherapy, High-Energy
1
2008
50
0.100
Why?
Adolescent
5
2018
8917
0.100
Why?
Receptor, erbB-2
2
2011
186
0.100
Why?
Gene Knockdown Techniques
3
2017
242
0.100
Why?
Radiosurgery
1
2011
220
0.100
Why?
Macrolides
2
2012
32
0.100
Why?
Radiotherapy, Computer-Assisted
1
2008
24
0.100
Why?
Proto-Oncogene Proteins c-akt
2
2010
320
0.100
Why?
Enteral Nutrition
2
2020
102
0.100
Why?
Patient Care
1
2009
86
0.100
Why?
Eicosanoids
1
2008
16
0.090
Why?
Lipoxygenase Inhibitors
1
2008
34
0.090
Why?
Skin
1
2012
553
0.090
Why?
Lymphoma, Non-Hodgkin
1
2010
259
0.090
Why?
Fallopian Tube Neoplasms
1
2008
36
0.090
Why?
Mutation, Missense
1
2010
274
0.090
Why?
Pain
2
2017
351
0.090
Why?
Pneumonia, Aspiration
1
2007
19
0.090
Why?
Cyclin-Dependent Kinase Inhibitor p16
1
2008
90
0.090
Why?
Technology, Radiologic
1
2008
101
0.090
Why?
Tumor Suppressor Protein p53
1
2010
363
0.090
Why?
Hypertension
1
2017
1188
0.090
Why?
Azacitidine
1
2008
122
0.090
Why?
Lung Diseases
1
2009
263
0.090
Why?
Tumor Burden
3
2013
282
0.090
Why?
Epidermal Growth Factor
1
2007
122
0.090
Why?
Tongue
1
2007
53
0.090
Why?
Protein Kinase C
1
2008
300
0.090
Why?
Regression Analysis
1
2009
614
0.090
Why?
Models, Biological
2
2015
1788
0.090
Why?
Uterine Neoplasms
1
2010
171
0.090
Why?
Continental Population Groups
1
2009
295
0.090
Why?
Oncogenes
1
2007
88
0.080
Why?
Multienzyme Complexes
2
2004
66
0.080
Why?
Triazines
1
2007
48
0.080
Why?
Cysteine Endopeptidases
2
2004
91
0.080
Why?
DNA Primers
3
2014
570
0.080
Why?
Proteasome Endopeptidase Complex
2
2004
100
0.080
Why?
Immunologic Factors
1
2008
160
0.080
Why?
Gastrointestinal Stromal Tumors
1
2006
25
0.080
Why?
Tachycardia, Supraventricular
1
2006
21
0.080
Why?
Genes, Tumor Suppressor
1
2007
163
0.080
Why?
Neoplasms, Hormone-Dependent
1
2006
39
0.080
Why?
Leiomyosarcoma
1
2006
32
0.080
Why?
Phospholipids
1
2006
122
0.080
Why?
Activin Receptors, Type I
1
2005
12
0.080
Why?
p38 Mitogen-Activated Protein Kinases
1
2006
120
0.080
Why?
Illinois
2
2007
449
0.080
Why?
Observation
2
2020
39
0.080
Why?
Base Sequence
4
2014
2422
0.080
Why?
Societies, Medical
2
2007
523
0.080
Why?
Receptors, Transforming Growth Factor beta
1
2005
42
0.080
Why?
Programmed Cell Death 1 Receptor
2
2019
151
0.080
Why?
Surgical Flaps
1
2008
261
0.080
Why?
Anticarcinogenic Agents
1
2006
73
0.080
Why?
Physician's Role
1
2007
185
0.080
Why?
Feasibility Studies
3
2017
715
0.080
Why?
Cholangiocarcinoma
1
2005
53
0.080
Why?
Adaptor Proteins, Signal Transducing
1
2007
279
0.080
Why?
Carbon Monoxide
1
2005
92
0.080
Why?
Interleukin-2
1
2006
283
0.080
Why?
Otorhinolaryngologic Surgical Procedures
1
2005
14
0.070
Why?
Proto-Oncogene Proteins c-kit
1
2005
82
0.070
Why?
Algorithms
3
2013
1821
0.070
Why?
Drug Interactions
1
2005
270
0.070
Why?
Hemorrhage
1
2006
239
0.070
Why?
Radiometry
1
2004
45
0.070
Why?
Reconstructive Surgical Procedures
1
2008
273
0.070
Why?
Speech Intelligibility
1
2004
10
0.070
Why?
Voice
1
2004
12
0.070
Why?
Leukemia
1
2006
295
0.070
Why?
Dose-Response Relationship, Radiation
2
2018
204
0.070
Why?
Oligonucleotides, Antisense
1
2004
69
0.070
Why?
Case-Control Studies
2
2006
1792
0.070
Why?
Pyrrolidines
1
2004
56
0.070
Why?
Taste
1
2004
26
0.070
Why?
Loss of Heterozygosity
2
2017
85
0.070
Why?
Multicenter Studies as Topic
1
2004
152
0.070
Why?
Administration, Topical
1
2003
98
0.070
Why?
Carcinoma, Transitional Cell
1
2005
144
0.070
Why?
Fibroblast Growth Factors
1
2004
79
0.070
Why?
Protease Inhibitors
1
2004
74
0.070
Why?
Nausea
1
2005
167
0.070
Why?
Radiation Tolerance
1
2004
174
0.070
Why?
Logistic Models
3
2018
1158
0.070
Why?
Thyroid Neoplasms
1
2008
427
0.070
Why?
Mitogen-Activated Protein Kinase 3
1
2003
72
0.070
Why?
Biopsy, Needle
1
2004
269
0.070
Why?
Vomiting
1
2005
176
0.070
Why?
Intubation, Gastrointestinal
1
2003
32
0.070
Why?
Amino Acid Sequence
3
2015
2159
0.070
Why?
Mastication
1
2004
66
0.070
Why?
DNA Methylation
1
2008
565
0.070
Why?
Lactones
1
2003
33
0.070
Why?
Disease Models, Animal
3
2017
2256
0.070
Why?
Bone Neoplasms
1
2006
321
0.070
Why?
Premedication
1
2003
58
0.070
Why?
In Situ Hybridization
1
2003
322
0.070
Why?
Hospitals, University
1
2003
201
0.070
Why?
Contrast Media
2
2009
1066
0.070
Why?
Cell Transformation, Neoplastic
1
2005
410
0.060
Why?
Mouth Mucosa
1
2003
73
0.060
Why?
Antineoplastic Agents, Hormonal
1
2004
147
0.060
Why?
Oligonucleotide Array Sequence Analysis
3
2010
702
0.060
Why?
Cause of Death
1
2004
273
0.060
Why?
STAT3 Transcription Factor
2
2013
70
0.060
Why?
Adenoviridae
1
2003
346
0.060
Why?
Carcinoma, Hepatocellular
1
2005
307
0.060
Why?
Drug Therapy, Combination
2
2019
978
0.060
Why?
Patient Care Team
1
2005
267
0.060
Why?
Registries
1
2006
631
0.060
Why?
Mitogen-Activated Protein Kinases
1
2003
233
0.060
Why?
RNA Interference
2
2017
377
0.060
Why?
Education, Medical, Continuing
1
2003
101
0.060
Why?
Interleukin-6
1
2003
228
0.060
Why?
Pilot Projects
2
2019
801
0.060
Why?
Adaptation, Psychological
1
2002
153
0.060
Why?
DNA Damage
2
2014
350
0.060
Why?
Referral and Consultation
1
2003
318
0.050
Why?
Glucocorticoids
1
2003
349
0.050
Why?
Apoptosis
3
2014
1763
0.050
Why?
Comorbidity
1
2004
895
0.050
Why?
Protein Structure, Tertiary
2
2015
766
0.050
Why?
Clinical Trials, Phase I as Topic
2
2011
150
0.050
Why?
T-Lymphocytes
2
2006
1276
0.050
Why?
Adaptive Immunity
1
2021
161
0.050
Why?
Tretinoin
1
2000
122
0.050
Why?
Infant
1
2006
3033
0.050
Why?
Tumor Necrosis Factor-alpha
1
2003
688
0.050
Why?
Sulindac
2
2009
11
0.050
Why?
Oral Health
1
2018
10
0.050
Why?
Activities of Daily Living
1
2019
187
0.050
Why?
Age of Onset
1
2018
313
0.050
Why?
Cooperative Behavior
2
2009
169
0.040
Why?
Social Participation
1
2017
13
0.040
Why?
Anorexia
1
2017
29
0.040
Why?
Metals
1
2018
89
0.040
Why?
Sensation Disorders
1
2017
21
0.040
Why?
Models, Molecular
2
2015
1302
0.040
Why?
Transcriptome
1
2021
466
0.040
Why?
Transfection
2
2010
942
0.040
Why?
African Americans
1
2005
1155
0.040
Why?
Dinoprostone
1
2017
69
0.040
Why?
Nerve Tissue Proteins
1
2021
527
0.040
Why?
Proteolysis
1
2017
93
0.040
Why?
Weight Loss
1
2019
214
0.040
Why?
Dyspnea
1
2017
80
0.040
Why?
ROC Curve
1
2019
749
0.040
Why?
Bronchoscopy
1
2017
137
0.040
Why?
Asian Continental Ancestry Group
2
2009
327
0.040
Why?
Polymerase Chain Reaction
2
2009
993
0.040
Why?
Decision Making
1
2002
615
0.040
Why?
Analgesics, Opioid
1
2020
354
0.040
Why?
Cell Line
2
2011
2598
0.040
Why?
Molecular Sequence Annotation
1
2015
75
0.040
Why?
Receptors, IgG
1
2015
49
0.040
Why?
Thalidomide
1
2015
54
0.040
Why?
Breast Neoplasms
2
2005
2735
0.040
Why?
Human papillomavirus 18
1
2014
15
0.040
Why?
Safety
2
2008
167
0.040
Why?
Protein Interaction Maps
1
2014
48
0.040
Why?
Sequence Alignment
1
2015
364
0.040
Why?
Erythrocyte Count
1
2013
23
0.030
Why?
Biopsy
2
2009
1167
0.030
Why?
Autopsy
1
2013
107
0.030
Why?
Genes, BRCA2
1
2014
147
0.030
Why?
DNA Copy Number Variations
1
2014
175
0.030
Why?
Genes, BRCA1
1
2014
187
0.030
Why?
Sequence Analysis, RNA
1
2014
193
0.030
Why?
Gastrostomy
1
2013
77
0.030
Why?
Immunoglobulin G
1
2015
469
0.030
Why?
Drug Synergism
1
2013
334
0.030
Why?
Germ-Line Mutation
1
2015
282
0.030
Why?
Herpesvirus 4, Human
1
2013
110
0.030
Why?
Ethers, Cyclic
1
2012
7
0.030
Why?
Macrophage Colony-Stimulating Factor
1
2012
19
0.030
Why?
Thrombospondin 1
1
2011
22
0.030
Why?
GPI-Linked Proteins
1
2011
52
0.030
Why?
Alleles
2
2006
1106
0.030
Why?
Enzyme Activation
1
2013
736
0.030
Why?
Caenorhabditis elegans
1
2014
202
0.030
Why?
Immunoenzyme Techniques
1
2012
328
0.030
Why?
Magnetic Resonance Imaging
1
2004
3179
0.030
Why?
Drug Dosage Calculations
1
2011
17
0.030
Why?
California
1
2011
134
0.030
Why?
Chemoradiotherapy, Adjuvant
1
2011
38
0.030
Why?
Lymphopenia
1
2011
30
0.030
Why?
Computational Biology
1
2015
525
0.030
Why?
Real-Time Polymerase Chain Reaction
1
2012
282
0.030
Why?
Thorax
1
2011
51
0.030
Why?
src-Family Kinases
1
2011
76
0.030
Why?
Organs at Risk
1
2011
44
0.030
Why?
DNA Breaks, Double-Stranded
1
2011
54
0.030
Why?
Gene Regulatory Networks
1
2013
275
0.030
Why?
Barrett Esophagus
1
2012
131
0.030
Why?
HEK293 Cells
1
2013
625
0.030
Why?
Cyclin D1
1
2010
81
0.030
Why?
Endonucleases
1
2010
21
0.030
Why?
Lymphoma, Mantle-Cell
1
2010
30
0.030
Why?
Leucovorin
1
2010
218
0.030
Why?
National Cancer Institute (U.S.)
1
2010
65
0.030
Why?
Histone Deacetylases
1
2010
61
0.030
Why?
Hospitals, Veterans
1
2009
19
0.030
Why?
Lymphoma, Follicular
1
2010
65
0.030
Why?
Extracellular Signal-Regulated MAP Kinases
1
2010
119
0.030
Why?
Paraffin Embedding
1
2010
75
0.030
Why?
Clinical Trials Data Monitoring Committees
1
2009
6
0.030
Why?
Chromosomes, Human, Pair 11
1
2010
107
0.030
Why?
Semaphorins
1
2009
17
0.030
Why?
Peptides
1
2013
632
0.030
Why?
Hydroxamic Acids
1
2009
48
0.030
Why?
Proto-Oncogene Proteins p21(ras)
1
2010
142
0.030
Why?
Leukemia, Lymphocytic, Chronic, B-Cell
1
2010
128
0.030
Why?
Lymphoma, Large B-Cell, Diffuse
1
2010
122
0.030
Why?
Molecular Sequence Data
1
2015
3186
0.030
Why?
Pneumonia
1
2010
149
0.030
Why?
Wound Healing
1
2012
347
0.030
Why?
Mutagenesis, Site-Directed
1
2010
282
0.030
Why?
Transplantation, Heterologous
1
2010
363
0.030
Why?
Carcinoma, Neuroendocrine
1
2009
25
0.020
Why?
Hematinics
1
2008
9
0.020
Why?
Phorbol Esters
1
2008
30
0.020
Why?
Demography
1
2009
160
0.020
Why?
Bone Marrow
1
2010
414
0.020
Why?
Inhibitory Concentration 50
1
2008
63
0.020
Why?
Community Health Services
1
2009
69
0.020
Why?
Postoperative Care
1
2009
234
0.020
Why?
Genes, erbB-1
1
2008
16
0.020
Why?
Cytochrome P-450 CYP3A
1
2008
42
0.020
Why?
Cell Cycle
1
2010
517
0.020
Why?
Blotting, Western
1
2010
832
0.020
Why?
Drug Delivery Systems
1
2009
206
0.020
Why?
Cytochrome P-450 Enzyme System
1
2008
78
0.020
Why?
Flow Cytometry
1
2010
722
0.020
Why?
Exons
1
2009
455
0.020
Why?
Topotecan
1
2007
45
0.020
Why?
Mice, Inbred Strains
1
2008
330
0.020
Why?
ATP-Binding Cassette Transporters
1
2008
142
0.020
Why?
Health Transition
1
2007
2
0.020
Why?
Blood Pressure
1
2013
1178
0.020
Why?
Tamoxifen
1
2008
164
0.020
Why?
Fluoroscopy
1
2007
123
0.020
Why?
Tumor Cells, Cultured
1
2008
1080
0.020
Why?
Gene Expression Regulation, Enzymologic
1
2008
223
0.020
Why?
Academic Medical Centers
1
2009
386
0.020
Why?
Cell Nucleus
1
2009
582
0.020
Why?
Video Recording
1
2007
190
0.020
Why?
Aging
1
2011
670
0.020
Why?
African Continental Ancestry Group
1
2009
551
0.020
Why?
Urogenital Neoplasms
1
2005
16
0.020
Why?
Stem Cells
1
2008
344
0.020
Why?
Mandibular Diseases
1
2005
17
0.020
Why?
Ethnic Groups
1
2009
466
0.020
Why?
Body Mass Index
1
2009
757
0.020
Why?
Polyethylene Glycols
1
2008
389
0.020
Why?
Pleural Effusion
1
2004
47
0.020
Why?
Up-Regulation
1
2008
705
0.020
Why?
Central Nervous System Neoplasms
1
2005
77
0.020
Why?
Gastrointestinal Neoplasms
1
2005
100
0.020
Why?
Genital Neoplasms, Female
1
2005
84
0.020
Why?
Sequence Deletion
1
2005
213
0.020
Why?
Receptors, Endothelin
1
2004
13
0.020
Why?
Antidiarrheals
1
2004
14
0.020
Why?
Research
1
2005
256
0.020
Why?
Benzamides
1
2005
187
0.020
Why?
Biomedical Research
1
2008
346
0.020
Why?
Neoplasm Proteins
1
2008
540
0.020
Why?
Bilirubin
1
2004
127
0.020
Why?
European Continental Ancestry Group
1
2009
1059
0.020
Why?
Transforming Growth Factor beta
1
2005
283
0.020
Why?
Genome-Wide Association Study
1
2011
1474
0.020
Why?
Gadolinium DTPA
1
2004
263
0.020
Why?
Hematologic Neoplasms
1
2005
285
0.020
Why?
Biological Availability
1
2002
104
0.020
Why?
Risk
1
2004
692
0.020
Why?
Cytokines
1
2006
742
0.020
Why?
Drug Monitoring
1
2002
105
0.010
Why?
Child
1
2012
6523
0.010
Why?
Severity of Illness Index
1
2007
1740
0.010
Why?
Muscle, Skeletal
1
2004
443
0.010
Why?
Diagnosis, Differential
1
2005
1586
0.010
Why?
Colonic Neoplasms
1
2004
547
0.010
Why?
Phenotype
1
2005
2242
0.010
Why?
Liver
1
2004
1217
0.010
Why?
Anti-Bacterial Agents
1
2004
784
0.010
Why?
Genetic Variation
1
2004
1349
0.010
Why?
Genetic Predisposition to Disease
1
2005
2182
0.010
Why?
Vokes's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_